Sociomedical scientist Robert Fullilove joins TWiV to discuss disparities in minority health; FDA announces an EUA on Yale’s SalivaDirect, protection of the upper and respiratory tract of mice after intranasal inoculation with an adenovirus-vectored SARS-CoV-2 spike gene, and listener questions.

TWiV reviews a new H1N1 swine influenza virus from China with pandemic potential, Ad5 vectored SARS-CoV-2 oral vaccine candidate, Operation Warp Speed vaccine candidates, FDA guidance on vaccine approval, and answer listener email.

The TWiV team reveals the repertoire of anti-viral antibodies in newborn humans, and a complement protein that binds the adenovirus capsid and prevents release of the viral DNA.

Vincent travels to Microbiotix, Inc, a biopharmaceutical company in Worcester, MA to speak with four members of the company about their discovery and development of small molecule drugs that target serious infectious diseases.

At the University of Zürich, Vincent speaks with virologists Cornel Fraeful, Urs Greber, and Silke Stertz about their careers and their work on AAV2, adenovirus entry, and influenza virus.

At the Glasgow Science Festival microTALKS, Vincent speaks with Ruth, Glen, and Esther about their research on viruses and Hodgkin lymphoma, adenovirus structure and entry into cells, and interactions between arthropod borne viruses and their hosts.

This episode of TWiV was recorded before an audience at the Beth Israel Deaconess Medical Center, where Vincent and Alan spoke with Dan and Jeff about AIDS vaccines.